• Newsroom >
  • News >
  • TBS Osteo: a trusted bone health solution in the world’s top hospitals

press release

TBS Osteo: a trusted bone health solution in the world's top hospitals

Newsweek's World's Best Hospitals 2023 list offers a fitting moment to reflect on TBS Osteo™'s reach: the software is present in more than half of these top 250 hospitals, and trusted by 15 of the top hospitals on the list.

Share

Geneva, Switzerland — March 6, 2024

Newsweek’s World’s Best Hospitals 2023 list offers a fitting moment to reflect on TBS Osteo™‘s reach: the software is present in more than half of these top 250 hospitals, and trusted by 15 of the top hospitals on the list.

The widespread adoption of TBS Osteo™ in the world’s foremost hospitals marks a pivotal shift in clinical practice and bone health assessment globally — a departure from conventional methods, where assessment focused primarily on bone mineral density (BMD). With TBS® gaining prevalence in leading hospitals, there is a tangible acknowledgment of the importance of considering not just bone density but bone microarchitecture as well.

The integration of TBS Osteo™ into clinical practice also signals a shift away from a one-size-fits-all approach toward a more personalized, holistic evaluation of bone health. Clinicians are increasingly equipped to tailor interventions, treatments, and preventive strategies based on a comprehensive understanding of a patient’s bone microstructure — supporting more targeted, effective care.

About Medimaps

Medimaps (Medimaps Group SA) is a medtech AI company on a mission to help clinicians catch what routine imaging misses — every scan, every patient — for better care, building toward an era where healthy bones are the norm.

The creators of Trabecular Bone Score® (TBS®) — the global standard in bone microarchitecture assessment, cited in more than 35 international clinical guidelines and supported by 1,600+ peer-reviewed publications — Medimaps develops imaging software that helps clinicians see bone quality, not just bone density, and predict fracture risk from the imaging they already perform.

Following its merger with Radiobotics, an award-winning Danish MedTech company, Medimaps is building a clinical portfolio spanning the MSK care continuum — from TBS Reveal™, opportunistic bone fragility assessment from routine X-rays, to TBS Osteo™, for osteoporosis fracture risk assessment on DXA, to RBfracture™, designed to support emergency and radiology teams with detection of trauma-related findings on X-ray.

Medimaps is headquartered in Geneva, Switzerland, with offices in Denmark, France, and the US, with technology deployed in more than 90 countries. Medimaps is certified to ISO 13485:2016 and MDSAP. Learn more at medimaps.ai.

Media contact

Elyse Sims
Senior Director, Marketing and Communications
press@medimapsgroup.com


Share

Latest press releases


Press & investor updates

Get Medimaps announcements straight to your inbox.

Great! We’ve received your information.

Media and investor inquiries?

For interviews, assets, or investment information, get in touch with our team.